FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Fund ProfileiShares Genomics Immunology and Healthcare ETF
  • Fund Overview
  • Fund Data
  • Peer Comparison
  • Ownership & News
IDNA
iShares Genomics Immunology and Healthcare ETF ETF AnalysisComprehensive ETF analysis for iShares Genomics Immunology and Healthcare ETF (IDNA) including NAV, expense ratio, dividend yield, sector breakdown, and holdings data.ETF AnalysisIDNA
IDNA
iShares Genomics Immunology and Healthcare ETF
  • Fund Overview
  • Fund Data
  • Peer Comparison
  • Ownership & News
IDNA
  1. Home
  2. Screener
  3. iShares Genomics Immunology and Healthcare ETFIDNAETF
iShares Genomics Immunology and Healthcare ETF Logo

iShares Genomics Immunology and Healthcare ETF

ETF
🇺🇸IDNA•AMEX•Equity

Your view on IDNA

iShares Genomics Immunology and Healthcare ETF Logo

iShares Genomics Immunology and Healthcare ETF

ETFIShares
🇺🇸IDNA•AMEX•Equity
AUM (USD)$352.11M
Expense Ratio0.47%
Yield (TTM)0.73%
Holdings50

Sentiment

—

AUM (USD)

$352.11M

Expense Ratio

0.47%

Yield (TTM)

0.73%

Holdings

50

Sentiment

—
Fund Overview

Overview

What the fund invests in, who runs it, and what it costs.

iShares Genomics Immunology and Healthcare ETF (IDNA) is an Equity fund from iShares, listed since 2019, with $352.1M in assets under management, a 0.47% expense ratio and a NAV of $42.17 USD.

Overview for iShares Genomics Immunology and Healthcare ETF

Fund Type
ETF
Fund Issuer
IShares
Asset Class
Equity
Sector
Financial Services
Industry
Asset Management
Inception Date
June 11, 2019
Domicile
US
Website
ishares.com/us/products/308878/ishares-genomics-immunology-and-healthcare-etf
Fund Type
ETF
Fund Issuer
IShares
Asset Class
Equity
Sector
Financial Services
Industry
Asset Management
Inception Date
June 11, 2019
Domicile
US
Website
ishares.com/us/products/308878/ishares-genomics-immunology-and-healthcare-etf
Fund Type
ETF
Fund Issuer
IShares
Asset Class
Equity
Sector
Financial Services
Industry
Asset Management
Inception Date
June 11, 2019
Domicile
US
Website
ishares.com/us/products/308878/ishares-genomics-immunology-and-healthcare-etf

About this fund

The iShares Genomics Immunology and Healthcare ETF seeks to track the investment results of an index composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology, and bioengineering.

Fund Data

Price Chart

Market price history and trading volume.

Key Facts

Cost, yield, size, and the fund's reference data.

Equity

Expense Ratio

0.47%

Yield (TTM)

0.73%

AUM

$352.11M

Fund Details

NAV$42.17 USD
Holdings50
Average Volume127.5K
Inception DateJune 11, 2019
Asset ClassEquity
Fund IssuerIShares
DomicileUS
ISINUS46435U1925
CUSIP46435U192
NAV CurrencyUSD

Expense Ratio

0.47%

Dividend Yield (TTM)

0.73%

Assets Under Management

$352.11M

NAV

$42.17 USD

Holdings

50

Average Volume

127.5K

Inception Date

June 11, 2019

Asset Class

Equity

Fund Issuer

IShares

Domicile

US

ISIN

US46435U1925

CUSIP

46435U192

NAV Currency

USD

Expense Ratio

0.47%

Dividend Yield (TTM)

0.73%

Assets Under Management

$352.11M

NAV

$42.17 USD

Holdings

50

Average Volume

127.5K

Inception Date

June 11, 2019

Asset Class

Equity

Fund Issuer

IShares

Domicile

US

ISIN

US46435U1925

CUSIP

46435U192

NAV Currency

USD

Distributions · last 12 months

Semi-Annual · 2 payments

Ex-datePaidAmount
Jun 15, 2026Jun 18, 2026$0.1254
Dec 16, 2025Dec 19, 2025$0.1555
Total, 12 months$0.28 a share

Dividend yield (TTM) 0.73% = $0.28 paid per share in the 12 months to Nov 20, 2026 ÷ the $38.42 price. Past distributions; future payments can differ.

Data last updated: Nov 13, 2026, 08:11 AM

Sectors

How the fund's assets are split across sectors.

2 sectors
  • 1Health Care
    99.8%
  • 2Cash and/or Derivatives
    0.2%

Top sector

Health Care

Top weight

99.8%

Top 3 weight

100.0%

Holdings

The securities the fund owns, by weight.

61 positions
1MRNAMODERNA
12.64%
2GMAB.COGENMAB
6.34%
3TWSTTWIST BIOSCIENCE
5.12%
4REGNREGENERON PHARMACEUTICALS
4.53%
5BAYN.DEBAYER AG
4.48%
64502.TTAKEDA PHARMACEUTICAL
4.27%
7EXELEXELIXIS INC
3.95%
8VRTXVERTEX PHARMACEUTICALS
3.66%
9ROP.SWROCHE PS PAR AG
3.54%
10INCYINCYTE CORP
3.50%
11MRKMERCK & CO INC
3.48%
12RVMDREVOLUTION MEDICINES
3.26%
13SAN.PASANOFI SA
3.20%
14IPN.PAIPSEN SA
2.99%
15BNTXBIONTECH SE ADR
2.88%

Concentration

Total Holdings61
Top 10 Weight52.05%
Top HoldingMRNA
Top Weight12.64%
1MRNAMODERNA
12.64%
2GMAB.COGENMAB
6.34%
3TWSTTWIST BIOSCIENCE
5.12%
4REGNREGENERON PHARMACEUTICALS
4.53%
5BAYN.DEBAYER AG
4.48%
64502.TTAKEDA PHARMACEUTICAL
4.27%
7EXELEXELIXIS INC
3.95%
8VRTXVERTEX PHARMACEUTICALS
3.66%
9ROP.SWROCHE PS PAR AG
3.54%
10INCYINCYTE CORP
3.50%
11MRKMERCK & CO INC
3.48%
12RVMDREVOLUTION MEDICINES
3.26%
13SAN.PASANOFI SA
3.20%
14IPN.PAIPSEN SA
2.99%
15BNTXBIONTECH SE ADR
2.88%

Total Holdings

61

Top 10 Weight

52.05%

Top Holding

MRNA

Top Weight

12.64%

1MRNAMODERNA
12.64%$41.12M
2GMAB.COGENMAB
6.34%$20.63M
3TWSTTWIST BIOSCIENCE
5.12%$16.66M
4REGNREGENERON PHARMACEUTICALS
4.53%$14.75M
5BAYN.DEBAYER AG
4.48%$14.56M
64502.TTAKEDA PHARMACEUTICAL
4.27%$13.89M
7EXELEXELIXIS INC
3.95%$12.84M
8VRTXVERTEX PHARMACEUTICALS
3.66%$11.90M
9ROP.SWROCHE PS PAR AG
3.54%$11.52M
10INCYINCYTE CORP
3.50%$11.40M
11MRKMERCK & CO INC
3.48%$11.31M
12RVMDREVOLUTION MEDICINES
3.26%$10.62M
13SAN.PASANOFI SA
3.20%$10.41M
14IPN.PAIPSEN SA
2.99%$9.72M
15BNTXBIONTECH SE ADR
2.88%$9.38M

Total Holdings

61

Top 10 Weight

52.05%

Top Holding

MRNA

Top Weight

12.64%

Peer Comparison

Comparables

Funds similar to this one.

Side by side on what an ETF is compared on20 funds
FundAsset classExpense ratioAssetsHoldings
IDNAiShares Genomics Immunology and Healthcare ETFThis fundEquity0.47%$352M50

Comparable funds

  • DALIFirst Trust Dorsey Wright DALI Equity ETFSector Equity0.30%$94M6
  • DEWWisdomTree Global High Dividend FundInternational Equity0.58%$169M729
  • ECOWPacer Emerging Markets Cash Cows 100 ETFEquity0.70%$195M119
  • EMXFiShares ESG Advanced MSCI EM ETFEquity0.16%$161M561
  • EWOiShares MSCI Austria ETFEquity0.49%$174M21
  • FLEEFranklin FTSE Europe ETFEquity0.09%$101M575
  • IMOMAlpha Architect International Quantitative Momentum ETFEquity0.38%$139M53
  • JHPIJohn Hancock Investments - Preferred Income ETFFixed Income0.54%$232M218

More IShares ETFs

  • IBGCiShares iBonds Dec 2046 Term Treasury ETFFixed Income0.07%$56M7
  • IBGKiShares iBonds Dec 2054 Term Treasury ETFFixed Income0.07%$5M4
  • IBGLiShares iBonds Dec 2055 Term Treasury ETFFixed Income0.07%$6M4
  • IBGMiShares iBonds Dec 2056 Term Treasury ETFFixed Income0.07%$41M3
  • IBHFiShares iBonds 2026 Term High Yield and Income ETFFixed Income0.35%$601M32
  • IBHGiShares iBonds 2027 Term High Yield and Income ETFFixed Income0.35%$531M392
  • IBHHiShares iBonds 2028 Term High Yield and Income ETFFixed Income0.35%$481M194
  • IBHIiShares iBonds 2029 Term High Yield and Income ETFFixed Income0.35%$547M355
  • IBHJiShares iBonds 2030 Term High Yield and Income ETFFixed Income0.35%$201M283
  • IBICiShares iBonds Oct 2026 Term TIPS ETFFixed Income0.10%$74M1
  • IBIDiShares iBonds Oct 2027 Term TIPS ETFFixed Income0.10%$159M5
  • IBIEiShares iBonds Oct 2028 Term TIPS ETFFixed Income0.10%$288M6
Ownership & News

Fund Holders

Institutions that own shares of this fund.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for this company. Press releases and market coverage, newest first.

News

Latest Market News

News

Latest Market News